UPJOHN RESURRECTS OFFICE OF THE CHAIRMAN

UPJOHN RESURRECTS OFFICE OF THE CHAIRMAN top management structure with the elevation of three corporate senior vice presidents to the title of corporate executive vice president. Joining Chairman and Chief Executive Officer Theodore Cooper, MD, and President and Chief Operating Officer Lawrence Hoff in the office of the chairman will be: Mark Novitch, MD; William U. Parfet, and Ley Smith. Under the the restructuring, Novitch will continue to head the company's pharmaceutical research program, and he will also be responsible for medical affairs, pharmaceutical control and pharmaceutical regulatory affairs. He will continue to report to Cooper. Novitch has had operational responsibility for Upjohn pharmaceutical research and scientific affairs since 1984 when he joined the company after leaving FDA where he was deputy commissioner. Cooper and Novitch previously worked together in government when Cooper was Assistant Secretary for Health in the Ford Administration and Novitch was a staffer in the old Department of Health, Education and Welfare to FDA. Smith will head Upjohn's pharmaceutical marketing as head of the worldwide pharmaceutical business. Upjohn's corporate vice president and general manager for international pharmaceutical subsidiaries since 1986, Smith will report to Hoff. William U. Parfet will be responsible for Upjohn's consumer products, agricultural division, chemical division, and health care services and will also report to Hoff. The office of the chairman is a traditional Upjohn management profile, but the company has not operated under that structure since Cooper became chairman last July. The appointments also bring back a management title, executive vice president, that has been absent from the firm for several years. The last time the company had as many as five corporate officers in the office of the chairman was in 1983, when R.T Parfet was chairman, Preston Parish was vice chairman, William Hubbard was president and Cooper and Hoff were executive vice presidents. Cooper and Hoff were also the last Upjohn top managers to hold the executive vice president titles prior to the appointments of Novitch, William Parfet, and Statement of Ownership, Management and Circulation required by 39 U.S.C. 3685 for F-D-C REPORTS - "The Pink Sheet" - (ISSN 0734-6514) issued weekly except at Christmas at an annual subscription price of $495.00. The general headquarters and business offices are at 5550 Friendship Blvd., Suite One, Chevy Chase, MD 20815. Mr. Wallace Werble, Jr. is Publisher. Mr. Cole Palmer Werble and Mr. David Blue are Executive Editors. Mr. Timothy Harrington is Managing Editor, all at the above address. "The Pink Sheet" is owned by F-D-C REPORTS, Inc. Stockholders are: Mr. Wallace Werble, Jr. and Mr. Cole Palmer Werble, 5550 Friendship Blvd., Suite One, Chevy Chase, MD 20815. There are no known bondholders, mortgagees or other security holders. The average number of copies printed during the past 12 months was 5,000 with 4,465 distributed to paid circulation, and 32 given free distribution. The average number of copies not distributed was 503. The actual number of copies printed nearest the date of filing is 5,000, with 4,331 to paid circulation, 31 given free distribution, and 639 copies not distributed. Signed by Wallace Werble, Jr. Statement dated Nov. 3, 1988. Smith. In 1984, the office of the chairman was reduced to three with the retirement of Hubbard and Parish; Cooper and Hoff were given the titles of vice chairman and president, respectively. The reorganization coincides with important management challenges in the drug business brought about by the recent approvals of the antibaldness product Rogaine (topical minoxidil) and the nonsteroidal anti-inflammatory Ansaid (flurbiprofen). Cooper commented in a Nov. 18 press release that "these appointments and the expanded office of the chairman will provide senior management with improved communications channels, timeliness in decision-making and a truly integrated focus across all our operations." The reorganization also includes a number of appointments in the management tier below the office of the chairman. Joining Smith at the top of Upjohn's pharmaceutical marketing structure will be Harold Chappelear, who becomes corporate senior vice president for North American pharmaceutical operations and worldwide marketing support. Louis Schroeter, PhD, will report to Hoff as senior vice president for worldwide pharmaceutical manufacturing, engineering and distribution. Schroeter will also be responsible for the Chugai-Upjohn joint venture, which is developing erythropoeitin. Two other executives becoming vice presidents are: Donald R. Parfet, who will be in charge of administration, and Gerald Welch, who will be responsible for the agricultural division and report to William Parfet. Retaining the title of senior vice president is Daniel Witcher who will continue to be assistant to the president until his retirement in February. In the pharmaceutical division four new vice presidents will be: Jack Jackson (U.S. pharmaceutical sales), Fernando Leal (Japan, Pacific & Latin American pharmaceutical operations). Geoffrey Rodgers (Europe, Africa & Middle East pharmaceutical operations), and Peter Seaver (worldwide pharmaceutical marketing).